{
    "relation": [
        [
            "Company",
            "AbbVie",
            "Teva",
            "ACADIA Pharm.",
            "Impax Lab.",
            "Avanir Pharm.",
            "DepoMed",
            "Prothena",
            "Intra-Cellular",
            "Omeros",
            "Concord Medical",
            "Amicus Therapeutics",
            "Xenoport",
            "Adamas Pharm.",
            "Cellular Dynamics",
            "uniQure",
            "Navidea Bio.",
            "Minerva Neuro.",
            "Corium"
        ],
        [
            "Symbol",
            "ABBV",
            "TEVA",
            "ACAD",
            "IPXL",
            "AVNR",
            "DEPO",
            "PRTA",
            "ITCI",
            "OMER",
            "CCM",
            "FOLD",
            "XNPT",
            "ADMS",
            "ICEL",
            "QURE",
            "NAVB",
            "NERV",
            "CORI"
        ],
        [
            "Market value ($ millions)",
            "$85,348",
            "$43,513",
            "$2,224",
            "$1,654",
            "$971",
            "$773",
            "$566",
            "$520",
            "$464",
            "$349",
            "$342",
            "$309",
            "$281",
            "$185",
            "$185",
            "$182",
            "$127",
            "$105"
        ],
        [
            "YTD % Ch.",
            "2.6%",
            "30.6%",
            "-8.4%",
            "-6.1%",
            "69.3%",
            "16.8%",
            "-19.8%",
            "-9%",
            "20.6%",
            "47.8%",
            "87.7%",
            "-13.2%",
            "n/a",
            "-30.6%",
            "n/a",
            "-39.1%",
            "n/a",
            "n/a%"
        ]
    ],
    "pageTitle": "18 ways to profit on Parkinson\u2019s miracle cure | America's Markets",
    "title": "",
    "url": "http://americasmarkets.usatoday.com/2014/08/15/18-ways-to-bet-on-a-parkinsons-disease-cure/",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 0,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043060830.93/warc/CC-MAIN-20150728002420-00187-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 6535791,
    "recordOffset": 6513200,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{50515=August 3, 2015, 54413=June 25, 2015, 55624=July 31, 2015, 45166=August 4, 2015, 53088=March 3, 2015, 8426=By Matt Krantz August 15, 2014 8:00 am, 56945=January 9, 2015, 36965=Markets July 31, 2015 1:13 pm \u00b7 David Craig, 29501=Tech August 4, 2015 12:34 pm \u00b7 Trisha Thadani, 31355=Story Stocks August 4, 2015 9:10 am \u00b7 Jane Onyanga-Omara, 33185=Ask Matt August 4, 2015 6:30 am \u00b7 Matt Krantz, 49078=July 14, 2015, 40852=Tech July 30, 2015 11:32 am \u00b7 Mike Snider, 39051=Story Stocks July 31, 2015 7:55 am \u00b7 Jessica Estepa, 51779=July 22, 2015, 35229=Story Stocks August 3, 2015 9:10 am \u00b7 Jane Onyanga-Omara}",
    "textBeforeTable": "Below are the 18 companies that trade on major U.S. exchanges that list Parkinson\u2019s disease as one of the areas they have products to address or where ongoing research is focused: Let\u2019s hope there\u2019s a miracle cure in one of these companies\u2019 labs. Chart source: S&P Capital IQ Longer-term, though, it\u2019s a different story. The Parkinson\u2019s index is up nearly 40%, while the S&P 500 is up 15.5%. Chart source: S&P Capital IQ But while investors and Parkinson\u2019s sufferers alike are hoping for a definitive cure, it\u2019s still not here. And that might explain that while there are some big winners among the 18 stock, as a whole the group isn\u2019t doing all that great this year given how risky these stocks are. A custom equal-weighted index of the 18 stocks is up just 8% this year, narrowly ahead of the 6.3% gain by the S&P 500. Both AbbVie and Teva are massive companies where Parkinson\u2019s is just one of the many diseases being targeted. It stands to reason that smaller companies, with more speculative and early stage plays, could benefit proportionally more if they have success. Avanir (AVNR) and Prothena (PRTA) are two of the larger companies with promising",
    "textAfterTable": "Sources: S&P Capital IQ, USA TODAY research Parkinson's disease, Robin Williams, Buzz\u00a0 SHARE ON FACEBOOK SHARE ON TWITTER TWEET SHARE ON SMS SHARE ON WHATSAPP EMAIL Related News Biotech Potential Alzheimer's treatment boosts Biogen Biotech",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}